Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Calithera Biosciences, Inc. (NASDAQ: CALA).

Full DD Report for CALA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CALA)

Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Monster Beverage Corporation (NASDAQ:MNST), Infinera Corporation (NASDAQ:I...
Source: GlobeNewswire
Date: May, 16 2018 07:30
Calithera Biosciences misses by $0.05, misses on revenue
Calithera Biosciences (NASDAQ: CALA ): Q1 EPS of -$0.37 misses by $0.05 . Revenue of $5.19M (+23.9% Y/Y) misses by $2M . Press Release More news on: Calithera Biosciences, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 10 2018 17:01
Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights
-Initiated Randomized Phase 2 CANTATA Trial -Presented Preclinical Data at the American Association for Cancer Research SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discov...
Source: GlobeNewswire
Date: May, 10 2018 16:05
Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that three abstracts describing CB-839, the Company’s novel, oral...
Source: GlobeNewswire
Date: April, 25 2018 16:03
3 Things In Biotech, April 19: Let's Talk Genito-Urinary Cancer
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Check out an exclusive note on Bristol-Myers Squibb today. Click here to learn more about what you get from me! Welcome to ano...
Source: SeekingAlpha
Date: April, 20 2018 08:00
Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment
Stock Monitor: Athenex Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Calithera Biosciences, Inc. (NASDAQ: CALA ) ("Calithera"). If you want access to this report all you need to do is sign up now by...
Source: ACCESSWIRE IA
Date: April, 20 2018 07:40
Premarket Gainers as of 9:05 am (04/18/2018)
DCAR +27%  on preliminary Q1 update on its enterprise automotive business. More news on: DropCar, Inc., Medigus Ltd, Heat Biologics, Inc., Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 18 2018 09:15
Calithera's CB-839 Fast Track'd for advanced kidney cancer
The FDA designates Calithera Biosciences' (NASDAQ: CALA ) CB-839 for Fast Track review for the treatment, in combination with Exelixis' (NASDAQ: EXEL ) CABOMETYX (cabozantinib), of patients with metastatic renal cell carcinoma who have received one or two prior lines of therapy, including ...
Source: SeekingAlpha
Date: April, 18 2018 07:16
Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Source: GlobeNewswire
Date: April, 18 2018 07:01
Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018
SOUTH SAN FRANCISCO, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical research for its glutaminase inhibitor CB-839 will be s...
Source: GlobeNewswire
Date: April, 13 2018 08:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-214.604.604.704.50177,728
2018-08-204.504.554.6254.40342,368
2018-08-174.654.404.654.40182,987
2018-08-164.704.654.754.55148,181
2018-08-154.654.654.754.60807,533

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2024,800159,82915.5166Cover
2018-08-1730,79260,27451.0867Short
2018-08-1622,95144,49451.5822Short
2018-08-15532,015573,41492.7803Short
2018-08-1416,56873,92822.4110Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CALA.


About Calithera Biosciences, Inc. (NASDAQ: CALA)

Logo for Calithera Biosciences, Inc. (NASDAQ: CALA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CALA)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 10 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 01 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 10 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: March, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: CALA)

      Daily Technical Chart for (NASDAQ: CALA)


      Stay tuned for daily updates and more on (NASDAQ: CALA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CALA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CALA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CALA and does not buy, sell, or trade any shares of CALA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/